Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals · Prostate Cancer
Phase 2 / Phase 3
Completed
57
2025-12
Industry sponsor intelligence
Ferring PharmaceuticalsClinical Pipeline.
Lead-sponsor view of Ferring Pharmaceuticals's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 17
- Recruiting
- 0
- Active
- 0
- Completed
- 16
- Results posted
- 8
- Avg enrollment
- 192
Pipeline overview
Programs by phase and activity.
Velocity
Ferring Pharmaceuticals trials by start year
Study start year · indexed snapshot
Development
Trials by phase
13phase labels
Early Phase 10
Phase 11
Phase 25
Phase 37
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Desmopressin → | 10 | 0 | 2 | 4 | 0 | 0 |
| Degarelix → | 3 | 0 | 1 | 2 | 0 | 0 |
| Cetrorelix → | 1 | 0 | 0 | 1 | 0 | 0 |
| Carbetocin → | 2 | 1 | 1 | 0 | 0 | 0 |
| Atosiban → | 1 | 0 | 1 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
Ferring Pharmaceuticals · Adverse Drug Event
Not applicable
Completed
1,099,551
2025-12
A Study of Degarelix in Taiwanese Patients With Prostate Cancer
Ferring Pharmaceuticals · Prostate Cancer
Phase 3
Completed
110
2025-04
Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
Ferring Pharmaceuticals · Hyperphagia in Prader-Willi Syndrome
Phase 2
Completed
38
2025-03
Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)
Ferring Pharmaceuticals · Nocturia Due to Nocturnal Polyuria
Not applicable
Completed
1,087
2024-12
FIRMAGON® Intensive Drug Monitoring
Ferring Pharmaceuticals · Prostate Cancer
Not applicable
Completed
1,454
2024-09
A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
Ferring Pharmaceuticals · Postpartum Hemorrhage
Phase 1
Completed
40
2024-09
Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)
Ferring Pharmaceuticals · Infertility, Female
Phase 3
Completed
437
2024-05
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
Ferring Pharmaceuticals · Nocturia
Phase 2
Completed
302
2022-03
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
Ferring Pharmaceuticals · Nocturia
Phase 3
Completed
342
2019-09
Showing 10 of 16 studies
Search sponsor records
All Ferring Pharmaceuticals studies.
This page groups studies where Ferring Pharmaceuticals is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
17 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT00117286Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate CancerDec 18, 2025NCT04740645NOCDURNA PASS Study Using Registries in Denmark, Germany and SwedenDec 3, 2025NCT01220869A Study of Degarelix in Taiwanese Patients With Prostate CancerApr 13, 2025NCT01968187Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi SyndromeMar 27, 2025NCT04329975Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)Dec 20, 2024NCT05181800FIRMAGON® Intensive Drug MonitoringSep 27, 2024NCT05924321A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy SubjectsSep 3, 2024NCT03809429Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)May 13, 2024NCT03201419A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in AdultsMar 2, 2022NCT03089073Study of Minirin Melt® in Adult Patients With NocturiaFeb 5, 2021